The ability to keep our production and companion animals healthy has been hindered by the insufficient translation of breakthroughs in human therapeutics to veterinary medicines. Our Better DNA™ approach leverages advances in human therapies and applies them toward the development of more cost effective and efficacious animal therapeutics.
In addition, the need for efficient animal testing models to better predict human outcomes is high. The Better DNA™ approach enables the design of research animal models that more closely resemble human diseases.
Embedded Controllable Bioreactors (ECBs)
The ECB platform enables rapid design, construction, and optimization of DNA-based therapeutics in which in vivo protein expression can be controlled through ex vivo administration of small-molecule activator ligands. Novel approaches for gene therapy and cell engineering will enable customized therapies for dogs, cats, and horses.
Rapid, customizable transgene assembly for joint development of transgenic research models with targeted and tissue-specific expression, combined with the ability to regulate the level of gene expression.
We are seeking partners to collaborate with us in research areas including:
Opportunities in production and companion animal health, including chronic disease, vaccines, and antibiotic therapeutics or antibiotic alternatives
Research Animal Models
Opportunities in improving research animal models through the development and utilization of our UltraVector® platform
To discuss collaboration opportunities, click the link below to contact us.